Although MRI detects radiorecurrent cancer overall, it may not accurately locate all lesions in the prostate gland. Investigators studied the role of MRI for detecting radiorecurrent prostate cancer for salvage focal therapy.
Study findings suggest that barriers exist in equitable administration of novel hormone therapy. Underuse of novel hormonal therapy agents in Black men with advanced prostate cancer continues and may be detrimental to their health.
The phase 3 PACE-B trial demonstrated that stereotactic body radiation therapy is noninferior to conventional radiation therapy for low- and favorable-intermediate-risk prostate cancer with respect to biochemical clinical failure. Stereotactic body radiation therapy is noninferior to conventional external beam radiation therapy for low- and favorable-intermediate-risk prostate cancer.
Identifying surrogate endpoints for use in clinical trials that strongly predict clinical outcomes such as improved survival and quality of life is challenging.